Showing 2461-2470 of 4263 results for "".
DermwireTV — Revance’s Neurotoxin Promising, Celebs Fight Melanoma with L’Oreal
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-revance-rsquo-s-neurotoxin-promising-celebs-fight-melanoma-with-l-rsquo-oreal/19138/In this weeks DermwireTV, patient safety is explored, L'Oreal supports melanoma research and Revance reports positive data for novel neurotoxin.DermwireTV — Nestle acquires Galderma; Dermatologic procedures surge
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-nestle-acquires-galderma-dermatologic-procedures-surge/19157/In this edition of DermWireTV, from the publishers of Practical Dermatology® magazine: Nestle acquires Galderma, dermatologic procedures surge, and we look ahead to the annual meeting in Denver. #DermWireDermwireTV — A big name is getting bigger; ICD-10 looms
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-mdash-a-big-name-is-getting-bigger-icd-10-looms/19163/In this premiere edition of DermWireTV, from the publishers of Practical Dermatology® magazine, we take a look at the latest acquisition by Valeant Pharmaceuticals, Inc., explore new data for Galderma's Mirvaso for rosacea, and get insights on the ICD-10 code set transition. #DermWireClinical Focus: Acne: Back in the Spotlight: Effective Options for Truncal Acne
https://practicaldermatology.com/topics/general-topics/back-in-the-spotlight-effective-options-for-truncal-acne/22031/Data suggest that patients may be unlikely to report truncal acne. Clinicians must assess chest and back involvement and be prepared to offer effective treatments.Understanding PML and Risks Associated with Biologic Therapies
https://practicaldermatology.com/topics/psoriasis/PD0509_10-php/22832/A swarm of controversy has enveloped biologics due to concerns about progressive multifocal leukoencephalopathy.Experts React to Latest Benzene Analysis
https://practicaldermatology.com/series/dermwire-tv/experts-react-to-latest-benzene-analysis/29810/In this week's DermwireTV, Practical Dermatology Editorial Board members provide their thoughts on the recent analysis examining benzene concentrations in BPO products; Johnson & Johnson seeks new indications for IL-23 inhibitor Tremfya; and the founder and CEO of Terns discusses plans to improvCultural and Aesthetic Considerations in Patients with Skin of Color
https://practicaldermatology.com/programs/practical-dermatology/cultural-and-aesthetic-considerations-in-patients-with-skin-of-color/24211/Culture is influenced by the prevalent art, customs, religions, and social institutions of one’s environment. As the human population continues to evolve, the world population is becoming more multicultural and multiethnic. By the year 2050, approximately 50% of the US population will include peopleStrength in Numbers: Assessing Your Financial Position
https://practicaldermatology.com/topics/practice-management/strength-in-numbers-assessing-your-financial-position/23863/Look at your ratios and ranges to make sure you are keeping up with industry—and economic—shifts.An Update on the Use of Trifarotene for the Treatment of Acne
https://practicaldermatology.com/columns/clinical-focus-1/an-update-on-the-use-of-trifarotene-for-the-treatment-of-acne/23267/Trifarotene is the first novel topical retinoid approved for the treatment of facial and truncal acne in 20 years.Viewpoint: What Does Private Equity in Dermatology Mean for Residents and Millennial Dermatologists?
https://practicaldermatology.com/youngmd-connect/resident-resource-center/viewpoint-what-does-private-equity-in-dermatology-mean-for-residents-and-millennial-dermatologists/23107/One resident’s take on the pros and cons of PE-backed employment and other opportunities for new dermatologists.